bcl-6

BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.

BI-3812 is an inhibitor of BCL6. Which inhibiting the BTB domain of BCL6 (IC50: 3 nM). BI-3812 also has antitumor activity.

CID5721353 (BCL6 inhibitor) is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor) that disrupts BCL6/corepressor complexes in vitro and in vivo, and was shown to bind the critical site within the BTB groove.

FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).

BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.

Glycochenodeoxycholic Acid (Lithocholylglycine) is a glycine conjugate of lithocholic acid, a bile acid. It is increased in livers of mice that are fed diets supplemented with ursadeoxycholic acid. Glycolithocholic acid levels are decreased in lean mice treated with obestatin. Serum glycolithocholic acid levels increase with age in children.

ARV-393 HCl is an orally active and potent PROTAC targeting BCL6 with antitumor activity for the study of non-Hodgkin's lymphoma.

ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).

OICR11029 is a potent probe for Bcl-6.

TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).

BI-3802, a highly potent BCL6 degrader, targets and inhibits the Bric-à-brac (BTB) domain of BCL6, exhibiting an IC50 value of ≤3 nM. It induces polymerization of BCL6 and facilitates its degradation in a manner dependent on the E3 ligase SIAH1, demonstrating notable antitumor activity[1][2].

Compound WK692 (compund WK692) is a BCL6 inhibitor that effectively suppresses the growth of diffuse large B-cell lymphoma cells without toxic side effects and acts synergistically with inhibitors of EZH2 and PRMT5.

BMS-986458 is an oral heterobifunctional degrader that targets the Cereblon (CRBN) E3 ubiquitin ligase. By binding to the BTB domain of BCL6, it induces the formation of a ternary complex between BCL6 and CRBN, thereby promoting the ubiquitination and proteasomal degradation of BCL6. BMS-986458 exhibits high selectivity for BCL6 degradation while showing weak degradation activity toward known new CRBN substrates (such as Ikaros, Aiolos, SALL4, and GSPT1), making it a valuable tool for studying BCL6-related tumor signaling pathways and antitumor mechanisms.

MNN-02-155 is a bivalent molecular glue that can simultaneously interact with both p300/CBP and BCL6. It effectively induces the activation of BCL6-targeted reporter genes and promotes cell death. This compound is used in the research of diffuse large B-cell lymphoma (DLBCL).

BCL6ligand-4 is a BCL6 ligand used in the synthesis of PROTACs, such as BCL6PROTAC 1.

BCL6 ligand-9 is a BCL6 ligand and serves as a ligand for Target Protein for PROTAC. It is used in the synthesis of PROTACBCL6Degrader-3.

PROTAC BCL6/GSPT1 Degrader-1 is a dual-target PROTAC degrader aimed at BCL6 and GSPT1. It inhibits cell proliferation, promotes DNA damage, and induces cell cycle arrest and apoptosis (apoptosis) in diffuse large B cell lymphoma. PROTAC BCL6/GSPT1 Degrader-1 is applicable for research in tumors such as lymphoma.

PROTAC BCL6Degrader-3 (compound 92) is a BCL6 PROTAC degrader. It is applicable for research in cancer or autoimmune diseases.

Glycochenodeoxycholic acid sodium salt is a bile salt formed in the liver from deoxycholic acid and glycine that induces apoptosis in hepatocytes. It acts as a detergent, dissolves fats for absorption, and is itself absorbed.

BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it valuable for tumor-related research [1].

CCT374705, an orally active BCL6 inhibitor, exhibits potent antiproliferative effects in vitro and effectively inhibits tumor growth in a lymphoma xenograft mouse model [1].

BCL6-IN-7 (BCL6 inhibitor-7) is a BCL6 co-repressor interaction inhibitor with potential anticancer activity. It can be used for studying lymphomas.

JWZ-7-7-Neg1, a neighboring transcription chemical inducer (TCIP), serves as a negative control. It exhibits reduced binding capabilities to BRD4 or BCL6 compared to JWZ-7-7, resulting in lower cytotoxicity towards DLBCL cells.

BCOR(498-514), biotinylated, is the smallest BCL6 binding domain with a KD of 1.32 µM. It can block BCL6-mediated transcriptional repression and induce cell death in lymphoma cells.